Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer Multicenter prospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback